Ibogaine: The Molecule, The Plant, and The Promise

Jim Mitchell
  • 5.0 (1)
  • Life Sciences
  • Series

This podcast presents a rigorous, graduate-level scientific deep dive into ibogaine — from its botanical origins through pharmacology, synthesis, clinical trials, and the next-generation analogs poised to reshape addiction medicine. Across ten episodes of approximately 45 minutes each, two expert co-hosts guide an audience of medicinal chemists, pharmacologists, and drug-development professionals through a complete narrative arc: plant → chemistry → mechanism → danger → analogs → clinic.

  1. Episode 1

    Ketanserin: From Cardiovascular Drug to "Naloxone for the Mind"

    Overview In this deep-dive episode, we explore the fascinating multi-decade journey of ketanserin tartrate—a molecule discovered at Janssen Pharmaceutica in 1980 that bridges cardiovascular pharmacology and modern psychedelic neuroscience[1]. Originally developed as a selective serotonin receptor antagonist for cardiovascular disorders, ketanserin has re-emerged in scientific literature as a pivotal candidate for a purpose-built "trip killer" and rescue agent in psychedelic-assisted therapy[4]. Key Highlights & Topics Covered The Molecule & Synthesis: An introduction to ketanserin's novel architecture—joining a quinazolinedione heterocycle with a 4-fluorobenzoylpiperidine fragment—and its discovery as the first selective 5-HT2A serotonin receptor antagonist[2].Clinical History & Overseas Legacy: A review of its clinical usage outside the United States under brand names such as Sufrexal and Ketensin for arterial hypertension, Raynaud's phenomenon, and topical wound-healing formulations[3].Pharmacological Profile: A detailed breakdown of its high-affinity competitive antagonism at 5-HT2A receptors, along with secondary actions at alpha-1 adrenergic and H1 histamine receptors[15].Why It’s Not in the US Pharmacopeia: An investigation into why ketanserin was never approved by the US FDA, focusing on its dose-dependent QTc interval prolongation driven by hERG potassium channel blockade[2], and how the 1980s market entry of ACE inhibitors and calcium channel blockers sidelined its US commercialization[20][21].The "Naloxone for the Mind" Breakthrough: How research evolved from Vollenweider’s 1998 trial proving 5-HT2A activation mediates psilocybin’s psychedelic effects[23][24] to Becker et al.’s 2023 University of Basel clinical trial showing that administering ketanserin during an LSD trip reduces acute session duration from 8.5 hours to 3.5 hours[4].Future in Psychedelic-Assisted Therapy: Why a mechanistically targeted 5-HT2A antagonist offers clinicians a cleaner, single-receptor safety net and abortive tool compared to off-label antipsychotics or sedatives[4].Target Audience Designed to bring both seasoned pharmaceutical researchers and casual listeners up to speed on the history, mechanism, safety profile, and clinical potential of ketanserin in modern neuropsychiatry

    Ketanserin: From Cardiovascular Drug to "Naloxone for the Mind"
See All Season 2 (1)

About

This podcast presents a rigorous, graduate-level scientific deep dive into ibogaine — from its botanical origins through pharmacology, synthesis, clinical trials, and the next-generation analogs poised to reshape addiction medicine. Across ten episodes of approximately 45 minutes each, two expert co-hosts guide an audience of medicinal chemists, pharmacologists, and drug-development professionals through a complete narrative arc: plant → chemistry → mechanism → danger → analogs → clinic.

Information